$2 Trillion Disappears Because of Fed's Secretive New Move

$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.

Michael P. Duffy net worth and biography

Michael Duffy Biography and Net Worth

SVP of Lantheus

Mike Duffy joined Lantheus Medical Imaging as Vice President, General Counsel and Secretary in 2008. Prior to joining Lantheus, he served as Senior Vice President, General Counsel and Secretary of Point Therapeutics, Inc., a Boston-based biopharmaceutical company. He has also served as General Counsel and in other leadership positions for several technology companies in the Boston area and in Washington, D.C. Mr. Duffy began his legal career with Ropes & Gray in Boston and holds law degrees from the University of Pennsylvania and Oxford University and an undergraduate degree from Harvard College.

What is Michael P. Duffy's net worth?: The estimated net worth of Michael P. Duffy is at least $9.77 million as of April 16th, 2021. Mr. Duffy owns 109,472 shares of Lantheus stock worth more than $9,774,755 as of December 21st. This net worth evaluation does not reflect any other assets that Mr. Duffy may own. Learn More about Michael P. Duffy's net worth.
How do I contact Michael P. Duffy?: The corporate mailing address for Mr. Duffy and other Lantheus executives is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. Lantheus can also be reached via phone at (978) 671-8001 and via email at [email protected]. Learn More on Michael P. Duffy's contact information.
Has Michael P. Duffy been buying or selling shares of Lantheus?: Michael P. Duffy has not been actively trading shares of Lantheus over the course of the past ninety days. Most recently, Michael P. Duffy sold 7,500 shares of the business's stock in a transaction on Friday, April 16th. The shares were sold at an average price of $21.75, for a transaction totalling $163,125.00. Following the completion of the sale, the senior vice president now directly owns 109,472 shares of the company's stock, valued at $2,381,016. Learn More on Michael P. Duffy's trading history.
Who are Lantheus' active insiders?: Lantheus' insider roster includes Minnie Baylor-Henry (Director), Gerard Ber (Director), Paul Blanchfield (Insider), John Bolla (COO), Michael Duffy (SVP), Mary Heino (CEO), Sam Leno (Director), Heinz Maeusli (Director), Brian Markison (CEO & Director), Robert Marshall, Jr. (CFO), Etienne Montagut (Insider), Daniel Niedzwiecki (Insider), Gary Pruden (Director), Andrea Sabens (CAO), and Carol Walker (SVP). Learn More on Lantheus' active insiders.
Are insiders buying or selling shares of Lantheus?: During the last year, Lantheus insiders bought shares 1 times. They purchased a total of 60,431,039 shares worth more than $57,409,487.05. During the last year, insiders at the medical equipment provider sold shares 13 times. They sold a total of 167,666 shares worth more than $12,647,453.05. The most recent insider tranaction occured on August, 12th when Director Gerard Ber sold 15,500 shares worth more than $1,495,440.00. Insiders at Lantheus own 1.5% of the company. Learn More about insider trades at Lantheus.
Information on this page was last updated on 8/12/2024.

Michael P. Duffy Insider Trading History at Lantheus

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/16/2021	Sell	7,500	$21.75	$163,125.00	109,472
3/8/2021	Sell	5,032	$19.16	$96,413.12
3/4/2021	Sell	1,737	$18.40	$31,960.80
12/9/2020	Sell	15,000	$14.00	$210,000.00	103,402
4/28/2020	Sell	7,198	$13.13	$94,509.74	133,402
3/6/2020	Sell	1,936	$14.58	$28,226.88	140,600
2/27/2020	Sell	1,552	$15.79	$24,506.08	116,493
11/14/2019	Sell	7,500	$20.79	$155,925.00	123,890
9/12/2019	Sell	7,500	$23.74	$178,050.00	131,390
9/4/2019	Sell	5,604	$20.60	$115,442.40	138,890
7/10/2019	Sell	8,819	$28.14	$248,166.66	144,494
4/29/2019	Sell	6,908	$24.84	$171,594.72	153,313
3/6/2019	Sell	1,789	$22.77	$40,735.53	160,221
4/3/2018	Sell	27,313	$15.30	$417,888.90	191,472
3/14/2018	Sell	11,492	$16.60	$190,767.20
1/10/2018	Sell	21,655	$22.40	$485,072.00	156,784
11/14/2017	Sell	11,917	$21.63	$257,764.71	152,301
9/11/2017	Sell	20,000	$16.45	$329,000.00	184,218
6/12/2017	Sell	20,000	$15.42	$308,400.00	188,234

Michael P. Duffy Buying and Selling Activity at Lantheus

Lantheus Company Overview

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Today's Range

Now: $89.29

$88.56

$91.69

50 Day Range

MA: $96.17

$76.22

$116.69

2 Week Range

Now: $89.29

$50.20

$126.89

Volume

2,181,956 shs

Average Volume

1,019,316 shs

Market Capitalization

$6.21 billion

P/E Ratio

14.86

Dividend Yield

N/A

Beta

0.45

Missed Nvidia? Buy Elon Musk’s “Silent Partner”

From Brownstone Research | Ad

In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my favorite stocks. Today, it’s probably the most popular stock in the world. I believe this Elon Musk “silent partner” could be the next big AI winner.

So please click here to see the details because a lot of people could get rich.